학술논문

PP225 Real-world data of ramucirumab plus docetaxel compared with docetaxel after immune-checkpoint inhibitors in stage IV non-small cell lung cancer patients
Document Type
Abstract
Source
In ESMO Open December 2022 7(6) Supplement 1
Subject
Language
ISSN
2059-7029